Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1725980
PUBLISHER: GlobalData | PRODUCT CODE: 1725980
GLP-1R Agonists - Label Extensions/Drug Repurposing: Market Overview
PUBLISHED:
PAGES: 73 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
This report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and obesity.
The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties.
GLP-1RAs are being investigated in different diseases in the metabolic, neurologic, and cardiologic markets.
Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants.
Scope
- Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation.
- Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing.
- Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas.
- Overview of current major players in the GLP-1RAs space and potential future players.
- GLP-1RAs global market outlook and deals overview.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future.
- Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Product Code: GDHCHT584
Table of Contents
Table of Contents
- 1 Preface
- 1.1 Contents
- 1.2 Abbreviations
- 1.3 Related Reports
- 2 Executive Summary
- 3 GLP-1R Agonists Overview
- 3.1 What Are GLP-1R Agonists
- 3.2 GLP-1R in the Body
- 3.3 History of GLP-1R Agonists
- 4 Industry Trends
- 4.1 Oral GLP-1Ras
- 4.2 Lower Dosing Frequency
- 4.3 Combination and Dual/Triple Agonists
- 4.4 Repurposing GLP-1Ras
- 5 Marketed Products
- 5.1 Global GLP-1RA Marketed Landscape
- 5.2 Marketed GLP-1Ras
- 5.3 Challenges and Opportunities in GLP-1RA Repurposing
- 5.4 Key Opinion Leader Perspectives on GLP-1RA Unmet Needs
- 6 Pricing and Reimbursement Assessment Case Study: Ozempic
- 7 Pipeline Analysis
- 7.1 Top 20 Indications with GLP-1RAs in Development
- 7.2 Top Five Therapeutic Areas with the Most GLP-1RA Pipeline Assets
- 7.3 GLP-1RA Pipeline Candidates
- 7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney Disease Treatment Landscape?
- 7.5 Where Are GLP-1RAs Expected to Position in the Future Heart Failure Treatment Landscape?
- 7.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment for Heart Failure and Chronic Kidney Disease
- 7.7 GLP-1RA Opportunities Beyond Planned Label Expansions
- 7.8 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Polycystic Ovary Syndrome
- 8 Opportunities and Challenges
- 8.1 Opportunities: the Role of GLP-1RAs in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
- 8.2 Opportunities: GLP-1RAs in Liver Diseases
- 8.3 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Liver Diseases
- 8.4 Opportunities: the Role of GLP-1RAs in Neurodegenerative Diseases
- 8.5 Opportunities: GLP-1RAs in Central Nervous System Disorders
- 8.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Parkinson's Disease
- 8.7 Opportunities: the Role of GLP-1RAs in Diastolic Heart Failure and Stroke
- 8.8 Opportunities: GLP-1RAs in Cardiovascular Diseases
- 8.9 Opportunities: the Role of GLP-1RAs in Chronic Kidney Disease
- 8.10 Opportunities: GLP-1RAs in Other Diseases
- 9 Companies
- 9.1 Current Major Player: Novo Nordisk
- 9.2 Current Major Player: Eli Lilly
- 9.3 Potential Future Players
- 9.4 Key Opinion Leader Perspectives on Future Players in the GLP-1RA Space
- 10 Market Outlook and Deals
- 10.1 GLP-1RA Global Market
- 10.2 Top 20 Major Deals and Acquisitions Between 2022 and 2025 with GLP-1Ras
- 11 Appendix
- 11.1 Bibliography
- 11.2 Primary Research - KOL Information
- 11.3 About the Authors
- 12 Contact Us
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.